Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials

Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials

Background and objective: TROPiCS-02 and EVER-132-002 are phase III randomized controlled trials (RCTs) comparing sacituzumab govitecan (SG) to treatment of physician’s choice (TPC) in patients with hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2−) locally r...

Full description

Saved in:
Bibliographic Details
Main Authors: Oleg Gluz, Binghe Xu, Rita Nanda, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Akanksha Sharma, Barinder Singh, Hope S. Rugo
Format: Article
Language:English
Published: SAGE Publishing 2025-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251320285
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items